Envisia

Envisia (Envisia Therapeutics, Inc.) was a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, spun out of Liquidia Technologies to apply PRINT (Particle Replication In Non-wetting Templates) particle-engineering to sustained-release ophthalmic therapeutics. Its lead candidate, ENV515 (travoprost) extended-release, was an intracameral implant intended to lower intraocular pressure in glaucoma patients for months from a single administration. The company was venture-backed by Canaan Partners, New Enterprise Associates, Morningside, and Batterson Venture Capital, and was acquired by Aerie Pharmaceuticals in October 2016. As a therapeutics company it exposes no public developer, API, or documentation surface, and its former web domains no longer resolve; this profile is retained as a VC-portfolio lead record with no API artifacts to enrich.

Envisia is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Ophthalmology.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsTherapeuticsOphthalmologyDrug DeliveryHealthcareClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/envisia: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: envisia
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/envisia.png
name: Envisia
description: Envisia (Envisia Therapeutics, Inc.) was a clinical-stage biopharmaceutical company based in Research Triangle
  Park, North Carolina, spun out of Liquidia Technologies to apply PRINT (Particle Replication In Non-wetting Templates) particle-engineering
  to sustained-release ophthalmic therapeutics. Its lead candidate, ENV515 (travoprost) extended-release, was an intracameral
  implant intended to lower intraocular pressure in glaucoma patients for months from a single administration. The company
  was venture-backed by Canaan Partners, New Enterprise Associates, Morningside, and Batterson Venture Capital, and was acquired
  by Aerie Pharmaceuticals in October 2016. As a therapeutics company it exposes no public developer, API, or documentation
  surface, and its former web domains no longer resolve; this profile is retained as a VC-portfolio lead record with no API
  artifacts to enrich.
url: https://raw.githubusercontent.com/api-evangelist/envisia/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Ophthalmology
- Drug Delivery
- Healthcare
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence